Abstract:Inactivation of the most important tumour suppressor gene TP53 occurs in most, if not all, human cancers. Loss of functional wild-type p53 is achieved via two main mechanisms: mutation of the gene leading to an absence of tumour suppressor activity and, in some cases, gain-of-oncogenic function; or inhibition of the wild-type p53 protein mediated by overexpression of its negative regulators MDM2 and MDMX. Because of its high potency as a tumour suppressor and the dependence of at least some established tumours on its inactivation, p53 appears to be a highly attractive target for the development of new anticancer drugs. However, p53 is a transcription factor and therefore has long been considered undruggable. Nevertheless, several innovative strategies have been pursued for targeting dysfunctional p53 for cancer treatment. In mutant p53-expressing tumours, the predominant strategy is to restore tumour suppressor function with compounds acting either in a generic manner or otherwise selective for one or a few specific p53 mutations. In addition, approaches to deplete mutant p53 or to target vulnerabilities created by mutant p53 expression are currently under development. In wild-type p53 tumours, the major approach is to protect p53 from the actions of MDM2 and MDMX by targeting these negative regulators with inhibitors. Although the results of at least some clinical trials of MDM2 inhibitors and mutant p53-restoring compounds are promising, none of the agents has yet been approved by the FDA. Alternative strategies, based on a better understanding of p53 biology, the mechanisms of action of compounds and treatment regimens as well as the development of new technologies are gaining interest, such as proteolysis-targeting chimeras for MDM2 degradation. Other approaches are taking advantage of the progress made in immune-based therapies for cancer. In this Review, we present these ongoing clinical trials and emerging approaches to re-evaluate the current state of knowledge of p53-based therapies for cancer.

Preferential translation of p53 target genes

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Inhibition of Nonsense-Mediated Decay Rescues Functional P53β/γ Isoforms in MDM2-amplified Cancers

Census and evaluation of p53 target genes

Variants of the 5′-terminal region of p53 mRNA influence the ribosomal scanning and translation efficiency

Post-translational regulation of p53 function through 20S proteasome-mediated cleavage

p53 translational-isoform Δ40p53 regulates cell cycle by modulating the miR-4671-5p/SGSH axis

Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin

Differential gene expression in cells with different p53 mutations identifies genome-wide p53 targets and shows distinct modulation of cellular pathways in response to DNA damage

The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells

Translating p53-based therapies for cancer into the clinic

Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression

Cellular adaptation to hypoxia and p53 transcription regulation

The Mettl3 epitranscriptomic writer amplifies p53 stress responses

Single-cell Transcriptomic Profiling of Non-Hematopoietic Circulating Cells in Mid-Gestational Mouse Embryos.

Putting p53 in Context

RNA represses p 53 translation by competing with HuR

Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26

p53 mRNA controls p53 activity by managing Mdm2 functions

Inhibition of Eukaryotic Translation Initiation Factor 5A (eIF5A) Hypusination Suppress p53 Translation and Alters the Association of eIF5A to the Ribosomes